Skip to main content

Genetic Advances and Translational Applications in Movement Disorders

48kviews
Editorial20 September 2023
Editorial: Genetic advances and translational applications in movement disorders

There are ongoing difficulties with clinic-genetic correlations in movement disorders (Gannamani et al., 2p21, Magrinelli. 2021). Cesaroni et al., illustrate the importance of defining a genetic diagnosis with atypical symptoms. They describe a patient with a rare intellectual disability syndrome related to a pathogenic variant in FOXP1. Together with the classical phenotype, they describe paroxysmal dystonia and discuss the potential pathogenic role of FOXP1 in the basal ganglia, which may lead to movement disorders in this population.In addition, Ando et al. describe the prevalence RFC1 mutation carriers in a large cohort of patients with ataxia, who had a younger age of onset than previously described, in comparison to more typical late-onset presentations (Cortese et al., 2019). As the causative role of intronic variants have been increasingly recognized as potentially common causes of genetic movement disorders, the inclusion of relevant intronic variants on gene panels and the assessment of repeat expansions are important to improve diagnosis (Beijer et al., 2013).More comprehensive tests, such as WES, are becoming more routine in the field of movement disorder as well. Zou et al. showed how WES allowed the identification of a new pathogenic variant in the PLA2G6 gene in two siblings allowing immediate management of the affect probands, and counseling for the family.Genetic counselling is a key principle of the management of rare neurogenetic disorders and this is particularly important in the fatal prion diseases. Appleby et al. in their review discuss the genetic associations in sporadic, acquired and genetic prion diseases and present the intricacies of genetic testing during life or at autopsy, in addition to the thorny ethical quandaries for testing of at-risk family members. They discuss the possibility of future treatments targeting the PRNP gene.Given the complexity of rare genetic disorders, there is increasing use of an interdisciplinary team-based approach, such as the Undiagnosed Disease Program (Mühlbӓck et al., 2023). In their paper, Huang et al. describe the important experience of the White Matter Rounds network, an international, collaborative platform where clinicians and scientists discuss challenging cases, promoting new understanding of these complex diseases and leveraging different expertise to aid in the diagnosis and facilitate research in white matter disorders leukodystrophies.There are understandable challenges in the design and implementation of clinical trials in rare neurological disorders. Videnovic et al highlight the lessons learned from clinical trials in pantothenate kinase-associated neurodegeneration, discussing successful strategies which can be applied to other rare and particularly metabolic movement disorders. They suggest multi-disciplinary engagement with experts and approaches concerning selection and recruitment of appropriate patients, trial endpoints and duration, special statistical considerations and the importance of regulatory feedback.Therefore, as genetic diagnosis become more relevant in the landscape of movement disorders, diagnostic and therapeutic approaches need to be reshaped to include new discoveries in clinical practice and maximize implementation of integrative resources from the clinical and research settings.

1,468 views

Study design challenges and strategies in clinical trials for rare diseases: Lessons learned from pantothenate kinase-associated neurodegeneration
Substantial challenges in study design and methodology exist during clinical trial development to examine treatment response in patients with a rare disease, especially those with predominant central nervous system involvement and heterogeneity in clinical manifestations and natural history. Here we discuss crucial decisions which may significantly impact success of the study, including patient selection and recruitment, identification and selection of endpoints, determination of the study duration, consideration of control groups including natural history controls, and selection of appropriate statistical analyses. We review strategies for the successful development of a clinical trial to evaluate treatment of a rare disease with a focus on inborn errors of metabolism (IEMs) that present with movement disorders. The strategies presented using pantothenate kinase-associated neurodegeneration (PKAN) as the rare disease example can be applied to other rare diseases, particularly IEMs with movement disorders (e.g., other neurodegeneration with brain iron accumulation disorders, lysosomal storage disorders). The significant challenges associated with designing a clinical trial in rare disease can sometimes be successfully met through strategic engagement with experts in the rare disease, seeking regulatory and biostatistical guidance, and early involvement of patients and families. In addition to these strategies, we discuss the urgent need for a paradigm shift within the regulatory processes to help accelerate medical product development and bring new innovations and advances to patients with rare neurodegenerative diseases who need them earlier in disease progression and prior to clinical manifestations.

8,707 views

31 citations

CASE REPORT
14 July 2023
Case report: Expanding the phenotype of FOXP1-related intellectual disability syndrome and hyperkinetic movement disorder in differential diagnosis with epileptic seizures
Carlo Alberto Cesaroni, 14 more and Carlo Fusco

4,890 views

4 citations

REVIEW
5 October 2022
Genetic aspects of human prion diseases
Brian S. Appleby, 1 more and Mohamed Elkasaby

22,001 views

62 citations

BRIEF RESEARCH REPORT
25 July 2022
The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders
Yu Tong Huang, 23 more and Roberta La Piana

4,300 views

8 citations

ORIGINAL RESEARCH
6 July 2022
Identification of a Novel Nonsense Mutation in PLA2G6 and Prenatal Diagnosis in a Chinese Family With Infantile Neuroaxonal Dystrophy
Yongyi Zou, 6 more and Yanqiu Liu

3,477 views

9 citations